Magrini Stefano Maria, Ricardi Umberto, Santoni Riccardo, Krengli Marco, Lupattelli Marco, Cafaro Ines, Scoccianti Silvia, Menichelli Claudia, Bertoni Filippo, Enrici Riccardo Maurizi, Tombolini Vincenzo, Buglione Michela, Pirtoli Luigi
Department of Radiation Oncology, University of Brescia, Brescia, Italy.
Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):788-99. doi: 10.1016/j.ijrobp.2006.01.026. Epub 2006 May 6.
To analyze the patterns of practice and survival in a series of 1722 adult astrocytoma patients treated in 12 Italian radiotherapy centers.
A total of 1722 patients were treated with postoperative radiotherapy (90% World Health Organization [WHO] Grade 3-4, 62% male, 44% aged >60 years, 25% with severe neurologic deficits, 44% after gross total resection, 52% with high-dose radiotherapy, and 16% with chemotherapy). Variations in the clinical-therapeutic features in three subsequent periods (1985 through 2001) were evaluated, along with overall survival for the different subgroups.
The proportion of women, of older patients, of those with worse neurologic performance status (NPS), with WHO Grade 4, and with smaller tumors increased with time, as did the proportion of those treated with radical surgery, hypofractionated radiotherapy, and more sophisticated radiotherapy techniques, after staging procedures progressively became more accurate. The main prognostic factors for overall survival were age, sex, neurologic performance status, WHO grade, extent of surgery, and radiation dose.
Recently, broader selection criteria for radiotherapy were adopted, together with simpler techniques, smaller total doses, and larger fraction sizes for the worse prognostic categories. Younger, fit patients are treated more aggressively, more often in association with chemotherapy. Survival did not change over time. The accurate evaluation of neurologic status is therefore of utmost importance before the best treatment option for the individual patient is chosen.
分析在意大利12个放疗中心接受治疗的1722例成年星形细胞瘤患者的治疗模式和生存情况。
共有1722例患者接受了术后放疗(世界卫生组织[WHO]3 - 4级患者占90%,男性占62%,年龄>60岁者占44%,有严重神经功能缺损者占25%,全切除术后患者占44%,接受高剂量放疗者占52%,接受化疗者占16%)。评估了三个连续时期(1985年至2001年)临床治疗特征的变化以及不同亚组的总生存率。
随着时间的推移,女性、老年患者、神经功能状态(NPS)较差、WHO 4级以及肿瘤较小的患者比例增加,在分期程序逐渐变得更准确之后,接受根治性手术、低分割放疗和更复杂放疗技术的患者比例也增加。总生存的主要预后因素为年龄、性别、神经功能状态、WHO分级、手术范围和放疗剂量。
最近,对于预后较差的类别,采用了更广泛的放疗选择标准,同时技术更简单、总剂量更小、分次剂量更大。年轻、身体状况良好的患者接受更积极的治疗,且更常联合化疗。生存率未随时间变化。因此,在为个体患者选择最佳治疗方案之前,准确评估神经功能状态至关重要。